Onxeo SA (Germany) Today
| C4X Stock | EUR 0.08 0.02 39.32% |
PerformanceOK
| Odds Of DistressAbout Average
|
Onxeo SA is trading at 0.0822 as of the 16th of March 2025. This is a 39.32% up since the beginning of the trading day. The stock's lowest day price was 0.0445. Onxeo SA has 48 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. The company has 111.06 M outstanding shares. More on Onxeo SA
Moving together with Onxeo Stock
Moving against Onxeo Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Onxeo Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Onxeo SA's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Onxeo SA or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Judith Greciet |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Onxeo SA (C4X) is traded on Frankfurt Exchange in Germany and employs 36 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Onxeo SA's market, we take the total number of its shares issued and multiply it by Onxeo SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Onxeo SA classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 111.06 M outstanding shares.
Onxeo SA has accumulated about 24.46 M in cash with (8.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Onxeo SA Probability Of Bankruptcy
Ownership AllocationOnxeo SA owns a total of 111.06 Million outstanding shares. Onxeo SA holds 13.25 pct. of its outstanding shares held by insiders and 12.72 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Onxeo Ownership Details
Onxeo SA Risk Profiles
Although Onxeo SA's alpha and beta are two of the key measurements used to evaluate Onxeo SA's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 8.96 | |||
| Semi Deviation | 9.74 | |||
| Standard Deviation | 13.17 | |||
| Variance | 173.5 |
Onxeo Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Onxeo SA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Onxeo SA Corporate Directors
| Elisabeth Carstensen | Director of Alliance Management, Member of the Executive Committee | Profile | |
| Caroline Lemarchand | Preclinical R&D Director, Member of the Executive Committee | Profile | |
| Aude Michel | Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | Profile | |
| Sonia Vallons | Quality Assurance Director, Member of the Executive Committee | Profile |
Other Information on Investing in Onxeo Stock
Onxeo SA financial ratios help investors to determine whether Onxeo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Onxeo with respect to the benefits of owning Onxeo SA security.